Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 8/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828598 | 0.72 | FDPS (0.41) | FDPSSMPD1LMNA | |
| SCHEMBL9502919 | 0.71 | FDPS (0.40) | FDPSLMNA | |
| SCHEMBL18486646 | 0.70 | FDPS (0.36) | FDPSLMNAPPARD | |
| SCHEMBL8193965 | 0.69 | FDPS (0.39) | FDPSLMNA | |
| SCHEMBL9126175 | 0.68 | FDPS (0.38) | FDPSSMPD1LMNA | |
| SCHEMBL18486439 | 0.67 | LMNA (0.39) | FDPSLMNAPPARD | |
| SCHEMBL5547549 | 0.67 | FDPS (0.46) | FDPSSMPD1PDE3ALMNAADRB3 | |
| SCHEMBL13186023 | 0.67 | LMNA (0.39) | FDPSLMNAPPARD | |
| SCHEMBL8710788 | 0.67 | FDPS (0.33) | FDPS | |
| SCHEMBL4835941 | 0.67 | FDPS (0.33) | FDPSPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8182789-B2 | Intermediate compound of technetium nitride complex for radiodiagnostic imaging | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MED-PHYSICS CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | MEN1, NCDN, C1R | FDPS 3370/4885SMPD1 3322/4885MEN1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.